Skip to content

Observing the clinical efficacy and safety of landiolol in non-stopping coronary artery bypass surgery: a single-center cohort study

Observing the clinical efficacy and safety of landiolol in non-stopping coronary artery bypass surgery: a single-center cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094104
Enrollment
Unknown
Registered
2024-12-17
Start date
2024-12-17
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Observation group:Intraoperative application of landiolol
Control group:None

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients undergoing CABG under non-stopping cardiac conditions; 2. Patients diagnosed with coronary atherosclerotic heart disease by the associate chief physician of cardiovascular medicine or cardiovascular surgery or above; 3. 30 years old or older; 4. Patients with transient atrial fibrillation who underwent surgery with sinus rhythm without amiodarone treatment.

Exclusion criteria

Exclusion criteria: 1. Persistent atrial fibrillation in the past; 2. Patients who received amiodarone as initial therapy for atrial fibrillation prior to initiation of beta-blocker therapy; 3. Patients with permanent pacemakers;4. Patients with severe cardiac dysfunction such as NYHA Class IV, left ventricular ejection fraction < 20%, cardiogenic shock and emergency CABG; 5. Patients with sinus bradycardia (resting heart rate < 50 beats/min, second or third degree atrioventricular block); 6. Patients with renal insufficiency who require dialysis; 7. Patients with airway diseases such as asthma or chronic obstructive pulmonary ventilation dysfunction; 8. Patients who have previously performed CABG; 9. Patients with cardiac arrest after CABG or combined with other valve operations.

Design outcomes

Primary

MeasureTime frame
Number of new cases of atrial fibrillation after operation;1 month postoperative mortality;3 month postoperative mortality;6 month postoperative mortality;

Secondary

MeasureTime frame
Length of postoperative stay;Duration of postoperative ventilator treatment;Duration of post-operative intensive care;Operation duration;Postoperative cardiokinase;Mean arterial pressure after surgery;Postoperative inflammatory factor;Postoperative left ventricular ejection fraction;Treatment cost;

Countries

China

Contacts

Public ContactJianjun Yang

The First Affiliated Hospital of Zhengzhou University

jianjunyang1971@163.com+86 137 8353 7619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026